Caprock Group LLC Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Caprock Group LLC trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 30.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 4,032 shares of the medical equipment provider’s stock after selling 1,781 shares during the period. Caprock Group LLC’s holdings in Hologic were worth $328,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Bessemer Group Inc. raised its holdings in Hologic by 8.0% in the 1st quarter. Bessemer Group Inc. now owns 10,892 shares of the medical equipment provider’s stock worth $848,000 after acquiring an additional 809 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in Hologic by 72.6% in the 1st quarter. Canada Pension Plan Investment Board now owns 453,913 shares of the medical equipment provider’s stock worth $35,387,000 after acquiring an additional 190,881 shares during the last quarter. 1832 Asset Management L.P. raised its holdings in Hologic by 6.2% in the 1st quarter. 1832 Asset Management L.P. now owns 27,417 shares of the medical equipment provider’s stock worth $2,137,000 after acquiring an additional 1,597 shares during the last quarter. BOKF NA raised its holdings in Hologic by 6.4% in the 1st quarter. BOKF NA now owns 10,508 shares of the medical equipment provider’s stock worth $800,000 after acquiring an additional 631 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after acquiring an additional 2,753,016 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on HOLX. Stephens restated an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and decreased their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. JPMorgan Chase & Co. boosted their target price on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Finally, UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, Hologic presently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Trading Up 0.3 %

Shares of HOLX stock opened at $78.97 on Friday. Hologic, Inc. has a 1 year low of $67.59 and a 1 year high of $84.67. The firm has a fifty day moving average price of $80.44 and a 200-day moving average price of $78.34. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market cap of $18.34 billion, a price-to-earnings ratio of 23.71, a PEG ratio of 2.48 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, equities analysts predict that Hologic, Inc. will post 4.27 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.